Drugs in Pipeline
12
Phase 3 Programs
5
Upcoming Catalysts
7
Next Catalyst
Dec 15, 2025
| Drug Name | Phase |
|---|---|
Placebo | Phase 3 |
Ruxolitinib | Phase 3 |
Selinexor (combination therapy) | Phase 3 |
Matching placebo for selinexor | Phase 3 |
Bortezomib | Phase 3 |
Selinexor | Phase 2 |
Selinexor 100 mg | Phase 2 |
Lenalidomide | Phase 2 |
KPT-8602 | Phase 2 |
Dexamethasone | Phase 2 |
Selinexor 60 mg | Phase 2 |
Hydroxyurea | Phase 2 |
7 upcoming, 0 past
Primary completion for Selinexor (combination therapy) trial (NCT04442022) in Relapsed/Refractory Diffuse Large B-cell Lymphoma
SourcePrimary completion for Ruxolitinib trial (NCT04562389) in Myelofibrosis
SourcePrimary completion for Selinexor trial (NCT04562389) in Myelofibrosis
SourcePrimary completion for Selinexor 60 mg trial (NCT05980806) in Myelofibrosis
SourcePrimary completion for Selinexor trial (NCT05611931) in Endometrial Cancer
SourcePrimary completion for Matching Placebo for selinexor trial (NCT05611931) in Endometrial Cancer
SourcePrimary completion for Selinexor trial (NCT04562870) in Myelofibrosis
Source